Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Intellect Neurosciences has obtained a notice of allowance and completed the grant requirements to obtain a European patent relating to the company's Antisenilin antibodies and products being developed for the treatment of Alzheimer's disease.
Subscribe to our email newsletter
The grant of the European patent is expected in several weeks. Other patents related to the Antisenilin antibodies have been granted in Japan, China and elsewhere. Patent applications are pending in the US. Intellect Neurosciences is the exclusive assignee of the Antisenilin patents, which are based on the invention of Daniel Chain, the company’s chairman and CEO.
Dr Chain said: “The use of Antisenilin monoclonal antibodies that specifically target the toxic forms of beta amyloid is at the forefront of the battle against Alzheimer’s disease. In addition to the company’s products in development, our invention has been applied to promising drug candidates in clinical development by major pharmaceutical companies.”